Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease ; volume:11 ; number:1 ; day:18 ; month:7 ; year:2019 ; pages:1-9 ; date:12.2019
Alzheimer's research & therapy ; 11, Heft 1 (18.7.2019), 1-9, 12.2019
- Creator
-
den Haan, Jurre
Csinscik, Lajos
Parker, Tom
Paterson, Ross W.
Slattery, Catherine F.
Foulkes, Alexander
Bouwman, Femke H.
Verbraak, Frank D.
Scheltens, Philip
Peto, Tunde
Lengyel, Imre
Schott, Jonathan M.
Crutch, Sebastian J.
Shakespeare, Timothy J.
Yong, Keir X. X.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-019-0516-x
- URN
-
urn:nbn:de:101:1-2019122219062320544847
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- den Haan, Jurre
- Csinscik, Lajos
- Parker, Tom
- Paterson, Ross W.
- Slattery, Catherine F.
- Foulkes, Alexander
- Bouwman, Femke H.
- Verbraak, Frank D.
- Scheltens, Philip
- Peto, Tunde
- Lengyel, Imre
- Schott, Jonathan M.
- Crutch, Sebastian J.
- Shakespeare, Timothy J.
- Yong, Keir X. X.
- SpringerLink (Online service)
Other Objects (12)
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population
Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population
Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population